Brief: Kiromic Biopharma Announces FDA Authorization Of IND To Initiate Phase 1 Clinical Trial Evaluating Deltacel In Non-Small Cell Lung Cancer
01/05/2023 13:12
May 1 (Reuters) - Kiromic Biopharma Inc KRBP.O :
* KIROMIC BIOPHARMA ANNOUNCES FDA AUTHORIZATION OF IND TO
INITIATE
PHASE 1 CLINICAL TRIAL EVALUATING DELTACEL IN NON-SMALL CELL
LUNG CANCER
* KIROMIC BIOPHARMA INC - EXPECTS BEGINNING OF FIRST IN
HUMAN
TRIAL ACTIVATION IN Q2 OF 2023
Source text for Eikon: ID:nBw8zZYV2a
Further company coverage: KRBP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kiromic Biopharma
See all newsBrief: Kiromic Biopharma Files For Offering Up To 1 Million Units
Brief: Kiromic Biopharma Applies To List Common Stock On The NYSE American Under Symbol 'KRBP'
Brief: Kiromic Biopharma Advances Deltacel-01 Into Expansion Phase Following Safety Monitoring Committee's Unanimous Recommendation
Brief: Kiromic Biopharma Reports Favorable Results At Six Weeks From Fourth Patient In Deltacel-01 Clinical Trial
Brief: Kiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial Site